MedPath

The effect of iron and omega-3 on coronary heart disease

Not Applicable
Conditions
Condition 1: Iron deficiency anaemia. Condition 2: Iron deficiency anaemia.
Iron deficiency anaemia, unspecified
Other iron deficiency anaemias
Registration Number
IRCT201301182709N27
Lead Sponsor
Tehran University of Medical Sciences and Health services
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
80
Inclusion Criteria

• Serum ferritin less than 12 ? g / l and serum iron of 60 mcg/100ml • Women in the range of 15 to 45 years of age • regular menstrual cycles • willingness to cooperate and fill the criteria of informed consent form to the project exclusion criteria: • smoking tobacco or alcohol • iron supplements, multivitamins and antioxidants in the last three months • the use of lipid-lowering drugs, oral contraceptives • the use of oral contraceptives • parasitic infections (those who have been diagnosed positive stool test will be excluded.) • thalassemia disease • kidney disease, liver disease, diabetes • local or systemic infection or inflammatory disease • history of ulcer disease or gastrointestinal bleeding or fibroids •malabsorption such as celiac sprue or steatorrhea • Any type of blood transfusion in the last 2 months of • pregnancy or lactation • not wanting to continue working • inadequate compliance supplement (compliance less than 80%) • change in diet or physical activity for any reason

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fasting serum ferritin. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: According ? g / l Lyazvn method.;Paraoxonase 1 activity. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: By U / L spectrophotometry.;Fasting serum ApoB levels. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: Based on Mg / dl Turbydymtry method.;Fasting serum concentrations of ApoA1. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: Based on Mg / dl Turbydymtry method.;Fasting concentrations of serum HS-CRP. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: Based on Mg / l immunohistochemical method Flumtryk.;Fasting serum iron. Timepoint: before the experiment.12 weeks after intervention. Method of measurement: According ? g / dl spectrophotometry.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath